BHT-3009

Parent company: Bayhill Therapeutics

• This DNA vaccine to myelin basic protein (MBP) contains the gene for MBP and is administered by intramuscular injection. This therapy is designed to cause immune tolerance, by reprogramming the immune system to modulate the response of the antigen-specific immune cells involved with MS. This would reduce the attack against the MBP in the myelin sheath.


• Preliminary studies indicate that the vaccine is safe and well tolerated. More studies may be forthcoming.